国药集团共裕有限公司、中国中药控股有限公司近期发布公告，将以计划安排的方式私有化中国中药，并拟在私有化要约完成后撤销中国中药的港交所上市地位，该交易总额约为港币156亿元。

海问律师事务所为要约人组成公司之一、中国国有企业混合所有制改革基金有限公司（“混改基金”）提供内地及香港法律服务；高伟绅律师事务所则作为要约人财务顾问中信证券的法律顾问参与交易。

这是今年迄今为止公布的规模最大的私有化交易。

要约人背后的私有化财团由混改基金、国药集团香港有限公司、先进制造产业投资基金二期、国新发展投资管理有限公司、重庆市涪陵实业发展集团有限公司及Red Investment Limited共同组成。

中国中药主要从事传统中药和医药产品的生产和销售，专注于中药配方颗粒、中成药和中药饮片。中国中药自1993年开始在港交所上市。

海问香港的合伙人伍祚隆领导了该项目中海问在香港法方面的工作；海问北京的合伙人林熙翔领导了该项目中海问在中国内地法律方面的工作；

高伟绅团队则由合伙人谭诗聪领导。

Haiwen, CC on China-TCM’s $2 bln take-private deal in HK

Sinopharm Common Wealth Company, an investment consortium led by Sinopharm Group, and China Traditional Chinese Medicine Holdings (China TCM) recently announced the take-private deal of China TCM through a scheme arrangement. Upon completion of the deal, China TCM will be delisted from the Hong Kong Stock Exchange. The total transaction amount is approximately $2 billion.

Haiwen & Partners serves as legal counsel to one of the consortium members of the offeror, China State-Owned Enterprise Mixed Ownership Reform Fund Limited ("Mixed Ownership Fund"), providing legal services in both Mainland China and Hong Kong. Meanwhile, Clifford Chance acts as the legal advisor to CITIC Securities, the financial advisor to the offeror.

This marks the largest take-private deal announced so far this year.

The consortium behind the offeror comprises the Mixed Ownership Fund, Sinopharm (Hong Kong), Advanced Manufacturing Industry Investment Fund Phase II, China Reform Development Investment Management, Chongqing Fuling Industry Development Group, and Red Investment Limited.

China TCM primarily engages in the production and sale of traditional Chinese medicine and pharmaceutical products, focusing on Chinese medicine granules, patent medicines, and Chinese medicinal slices. China TCM has been listed in Hong Kong since 1993.

The Haiwen team was led by partners Wu Zuolong and Lin Xixiang, advising on Hong Kong law and PRC law, respectively.

The Clifford Chance team saw the leadership of partner Tommy Tam.